Allogene Therapeutics Inc ALLO:NASDAQ

Last Price$18.32Cboe Real-Time Last Sale as of 1:55PM ET 12/01/21
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.17(0.92%)
Bid (Size)$18.29 (200)
Ask (Size)$18.33 (200)
Day Low / High$18.12 - 19.25
Volume421.6 K

View Biotechnology IndustryPeer Comparison as of 12/01/2021


Allogene Therapeutics Inc ( NASDAQ )

Price: $18.32
Change: -0.17 (0.92%)
Volume: 421.6 K
1:55PM ET 12/01/2021

PTC Therapeutics Inc ( NASDAQ )

Price: $36.56
Change: -0.60 (1.61%)
Volume: 168.0 K
1:55PM ET 12/01/2021

OPKO Health Inc ( NASDAQ )

Price: $4.00
Change: +0.06 (1.65%)
Volume: 2.0 M
1:52PM ET 12/01/2021

Ligand Pharmaceuticals Inc ( NASDAQ )

Price: $157.62
Change: -4.30 (2.66%)
Volume: 37.8 K
1:54PM ET 12/01/2021

ChemoCentryx Inc ( NASDAQ )

Price: $37.15
Change: +0.87 (2.40%)
Volume: 1.2 M
1:54PM ET 12/01/2021

Read more news Recent News

--Cowen Starts Allogene Therapeutics at Outperform
9:56AM ET 10/20/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

JMP Securities Adjusts Allogene Therapeutics' Price Target to $27 from $53, Keeps Market Outperform Rating
10:54AM ET 10/12/2021 MT Newswires

Allogene Therapeutics (ALLO) has an average rating of outperform and price targets ranging from $18 to $55, according to analysts polled by Capital IQ. (MT...

SMBC Nikko Initiates Coverage on Allogene Therapeutics With Outperform Rating, $42 Price Target
11:39AM ET 10/11/2021 MT Newswires

Allogene Therapeutics (ALLO) has an average rating of Outperform and price targets ranging from $18 to $55, according to analysts polled by Capital IQ. (MT...

After Hours Watch List Scorecard: VXRT, AGRX, ALLO
4:29PM ET 10/08/2021 MT Newswires

Here's how the stocks on Thursday's After Hours Watch List performed during today's regular session: AFTER HOURS REGULAR SESSION VXRT +11.3%...

Company Profile

Business DescriptionAllogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA. View company web site for more details
Address210 East Grand Avenue
South San Francisco, California 94080
Number of Employees122
Recent SEC Filing11/04/202110-Q
President, Chief Executive Officer & DirectorDavid D. Chang
Chief Financial OfficerEric Schmidt
Chief Scientific OfficerBarbra Sasu
Chief Technical OfficerAlison Moore

Company Highlights

Price Open$18.26
Previous Close$18.49
52 Week Range$12.90 - 39.12
Market Capitalization$2.6 B
Shares Outstanding142.5 M
SectorHealth Technology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.87
Beta vs. S&P 500N/A
Net Profit Margin-652.24%
Return on Equity-24.20%

Analyst Ratings as of 10/07/2021

Consensus RecommendationConsensus Icon
Powered by Factset